Skip to main content

Serum pepsinogen levels in different regions of China and its influencing factors: a multicenter cross-sectional study



The aim of this study is to investigate the difference of serum pepsinogen (PG) baseline levels in different regions of China and its influencing factors.


From October 2016 to October 2018, asymptomatic health checkup people who underwent nasal endoscopy in nine health management centers in different regions of China were collected. Lifestyle questionnaires were conducted, and serum PG and gastroscopy were performed. The differences in PG levels in baseline population (OLGA-0 grade) were studied according to geographical subregions of China. SPSS software was used for statistical analysis.


1922 patients were included in the final analysis. Compared with the non-atrophy (OLGA-0) group, PGR levels in atrophy group (OLGA-I to IV) were significantly decreased with the atrophy degree (p < 0.05). A total of 1590 baseline people (OLGA-0) were included in the study, including 254 from South China, 574 from East China, 210 from Southwest China, 332 from Northeast China, and 220 from Central/Northern China. There were significant differences in baseline PGI levels among the five regions (p < 0.05). The PGII levels were also different among the five regions, except for Central/Northern versus Southern China. PGR (PGI/PGII ratio) levels in Southern China were higher than other four regions. Further studies were conducted on the related factors that might affect the baseline PG level, which was affected by nationality, dietary habits, smoking, Helicobacter pylori infection and other related factors.


Influenced by many factors, the baseline PG levels are different in different regions of China. In the follow-up studies of PG cut-off value, different PG cut-off value based on region may be more effective in the screening of gastric cancer and precancerous lesions in China.

Peer Review reports


Serum Pepsinogen (PG) can reflect the morphological and functional status of gastric mucosa. Pepsinogen I (PGI) is a pointer to detect the cell function of gastric acid gland (fundus gland), and decreased when gastric acid secretion is decreased or gastric mucosal glands are atrophied. Pepsinogen II (PGII) is significantly correlated with gastric fundus mucosa lesions (compared with gastric antrum mucosa), and its elevation is correlated with gastric fundus duct atrophy, intestinal metaplasia or pseudopylori metaplasia, and dysplasia. Progressive reduction of PGR (PGI/PGII ratio) is associated with progressive gastric mucosal atrophy and gastric cancer [1]. Multiple studies have confirmed that serum PG is a potential serological marker for screening gastric cancer and atrophic gastritis [2, 3].

PG level is affected by many factors such as race, region, age, gender, height, weight, body surface area, smoking history, drinking history, Helicobacter pylori (Hp) and so on [4]. Multiple studies have found that the cutoff value of PG in the diagnosis of gastric atrophy is different in different countries. The Japanese standard, taking PGI ≤ 70 ng/ml and PGR ≤ 3 as the cut-off value, is most widely used at present, with the sensitivity of 66.7–84.6% and specificity of 73.5–87.1%, for the diagnosis of atrophic gastritiss [5,6,7]. A number of European studies suggested that the cut-off value for evaluating fundus atrophy was PGI ≤ 56 ng/ml (sensitivity: 61.9%, specificity: 94.8%), and PGR ≤ 5 (sensitivity: 75.0%, specificity: 91.0%) [8]. A study from South Korea suggested that PGI ≤ 70 ng/ml had a good sensitivity (72.4%), but a low specificity (20.2%) in the evaluation of atrophic gastritis, while the sensitivity and specificity of PGR ≤ 3 were 59.2–61.7% and 61.0% [9]. According to the results of our previous studies, the PGR cutoff value for diagnosis of atrophy and severe atrophy is around 4.28–9.08 [10], which is much higher than the standard of PGR < 3 in Japan. The same differences were found in many domestic studies [11, 12], which may be related to the different baseline levels of PG. China is a vast country, it is necessary to explore whether there are significant differences of the baseline PG levels among different regions. In view of this situation, we combined with several domestic health management centers to carry out this research. Gastroscopy and pathology were adopted as the gold standard to detect serum PG in asymptomatic health checkup people and to study the influencing factors of the baseline levels of PG.



This was a multicenter cross-sectional study of consecutive subjects who underwent regular health checkup from October 2016 to October 2018 at nine International Healthcare Centers in different regions of China, including Southern China (No. 924 Hospital of the People’s Liberation Army of China), Eastern China (the Second Affiliated Hospital of Zhejiang University College of Medicine, Zhongshan Hospital affiliated to Xiamen University, and Traditional Chinese Medicine Hospital of Kunshan), Southwest China (Sichuan Provincial People’s Hospital and the First Hospital affiliated to AMU [Southwest Hospital]), Northeast China (Jinlin People’s Hospital), and Central/Northern China (Chinese PLA General Hospital and Jingzhou Hospital of Traditional Chinese Medicine). All procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and the Helsinki Declaration of 1964 and later versions. Informed consent was obtained from all patients prior to enrolment. The study was approved and authorized by the ethics committees of various participating hospitals (approval #2015-079 at the Second Affiliated Hospital of Zhejiang University College of Medicine, the leading site).

Inclusion criteria were: (1) intention to undergo gastroscopy during health checkup examination; (2) 25–75 years of age. Exclusion criteria were: (1) a history of gastric ulcer, gastric polyp, or GC; (2) a history of gastrectomy; (3) treatment with a proton pump inhibitor in the last month; (4) contraindications to gastroscopy; (5) a history of Hp eradication; or (6) incomplete data.

Questionnaire survey

A self-reported questionnaire was used in the present study. It included baseline information (age, sex and nationality), living style (smoking [> 1 cigarette daily for more than 1 year; the number of cigarettes and duration of smoking were asked for smokers], alcohol consumption [any type of alcohol more than once weekly for more than 1 year; alcohol types and consumption frequency were asked for drinkers], eating habits (high-salt diet [salt > 10 g/day], green vegetables and fresh fruits [> three times per week]), and family history of GC among first-degree relatives.


The participants underwent gastroscopy and pathological examination of the biopsies, serum PG test, 13C-urea breath test (Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., China), and/or Hp serological current infection marker rapid test (MP Biomedicals, Santa Ana, CA, USA), all on the same day. All tests were performed according to the manufacturers’ instructions.

Hp infection was determined based on the 13C-urea breath test, Hp serological current infection marker rapid test, and pathological screening. Patients showing positive results for any of these three tests were considered to be Hp-positive. If all tests were negative, the patient was considered to be Hp-negative.

Fasting blood (5 ml) was collected from each subject and centrifuged for 10 min at ≥ 10,000g. Serum PG levels were assayed by the chemiluminescent microparticle immunoassay method with the Abbott ARCHITECT Pepsinogen I and II Reagent Kit (Abbott Laboratories Inc., Chicago, IL, USA).

Gastroscopy was performed by the double-blind method. Two biopsies were performed at the small curvatures of the gastric antrum and body, respectively. Additional biopsies were taken from the mucosal abnormalities. The biopsies were scored semi-quantitatively by two pathologists with > 10 years of experience, according to the updated Sydney classification system [13] and the OLGA (Operative Link on Gastritis Assessment) method, which combine the degree and range of gastric mucosa atrophy/intestinal metaplasia, which are internationally accepted and applied in the screening of GC and precancerous lesions [14]. In case of disagreement, the two pathologists discussed the data until consensus.

Statistical analysis

Statistical analysis was performed with SPSS 20 (IBM Corp., Armonk, NY, USA). Continuous data were tested for normal distribution by the Kolmogorov–Smirnov test. Data with normal distribution were expressed as mean ± standard deviation (SD), while data with skewed distribution were presented as median (interquartile ranges) (IQR), and compared by ANOVA with post hoc Scheffe’s test. Categorical data were presented as frequency and percentage, and analyzed by the chi-square test and Bonferroni post hoc test. p < 0.05 was considered statistically significant.


A total of 2256 subjects were included in the study. Totally 316 patients were excluded due to incomplete data, four due to a history of gastrectomy, five due to proton pump inhibitor use in the recent one month, and nine due to a history of gastric ulcer or gastric polyp. Finally, 1922 patients were included in the final analysis. The participants were 52.3 ± 9.8 years old. The male to female ratio was 1.2:1 (1065/857). There were 1590 participants in the OLGA-0 group, 185 in the OLGA-I group, 88 in the OLGA-II group, 43 in the OLGA-III group, 6 in the OLGA-IV group, and 10 in the gastric cancer (GC) group. There were no gender differences among the five groups. The age and Hp infection rate increased gradually with the increase of atrophy degree (Table 1).

Table 1 Age, sex and Hp infection rate in different groups

Serum PG differences among the pathological groups

Serum PG levels were compared among the NAG (non-atrophy group, OLGA-0 group), MAG (mile-moderate atrophy group, OLGA I-II group), SAG (severe atrophy group, OLGA III-IV group), and GC groups. Compared with NAG group, PG levels in atrophy group (OLGA-I to IV) were significantly different (p < 0.05). In addition, compared with the NAG group, PGI levels and PGRs in the MAG and SAG groups were significantly lower (p < 0.05). Compared with the MAG group, the SAG group had significantly lower PGRs (p < 0.05). PGR levels in the GC group were significantly lower than those of the NAG and MAG groups (p < 0.05). The PG levels between the SAG and GC groups had no significant differences (p > 0.05) (Table 2).

Table 2 The PG levels in different pathologic groups

Baseline PG levels in different regions

According to regional grouping, further analysis of the OLGA-0 group showed that PGI levels were significantly different among five regions in China. There were also significant differences in PGII levels among the five regions, except for Central/Northern versus Southern China. PGR levels in Southern China were higher than those of the other regions (Table 3).

Table 3 Differences in baseline PG levels in different regions (OLGA-0 group)

Analysis of the influencing factors of PG

Baseline data from five regions were further analyzed. There were significant differences in age, ethnicity, dietary habits, smoking and Hp infection rate among the five regions. In addition, except for the Eastern China, there is no difference in the proportion of ethnic minorities in the other four regions. The Hp infection rate was higher in the southwest (53.9%). People in Northeast China, Southwest China and Southern China had a higher proportion of high-salt diet (32.5%, 17.6% and 16.1%, respectively). Eastern China had the best consumption habits of fruits and vegetables (95.3% and 91.3% ate fruits and vegetables regularly, respectively). There was no difference in the consumption habits of vegetables in the other four regions. But Southern China had the least consumption habits of fruits (only 39.8%). Southwest China had the best dairy intake habit (42.9%), followed by Eastern China (31.2%), and the other three regions had no difference in dairy intake. Central/Northern China and Southern China had the highest smoking rate (42.7% and 31.4%, respectively), and Northeast China had the lowest smoking rate (11.7%) (Table 4).

Table 4 Differences in sex, age, smoking, dietary habits and Hp infection in different regions (OLGA-0 group)


The progression from chronic non-atrophic gastritis, via atrophic gastritis (AG) and intestinal metaplasia (IM), to dysplasia, termed Correa’s cascade [15], is widely considered a common evolution path of the intestinal type of noncardia GC. AG is the turning point, and represents a precancerous lesion [16,17,18]. The annual incidence rates of gastric cancer were found to be 0.1%, 0.25%, 0.6%, and 6% in patients with atrophic gastritis, intestinal metaplasia, mild-to-moderate dysplasia, and severe dysplasia within 5 years after diagnosis [19]. The OLGA classification is an effective way of classifying gastritis and grading cancer risk based on histopathological findings of biopsy specimens [20, 21]. Massimo Rugge’s prospective studies explored the association between OLGA classification and the risk for gastric cancer, and confirmed that OLGA staging reliably predicts the risk for development of gastric epithelial neoplasia [22, 23]. The high-risk stage (defined as stage III or IV of the OLGA classification) is closely associated with high risk of GC [22,23,24,25]. In this study, we found 17.3% (332/1922) of the total cases were diagnosed with AG; more specifically, 2.5% (49/1922) of the cases presented with severe AG (stage III and IV of the OLGA classification), in the asymptomatic health checkup population. And the PG levels especially PGR showed significant different. Effectively screening and management of those AG patients especially severe AG patients, making full use of non-invasive testing methods such as PG in general population, has a great significance in terms of reducing the incidence of GC and improving the early detection rate.

The mean Hp infection rate is 39.4%, which is similar with our past research [10]. The age and Hp infection rate increased with the increase of the atrophy degree, which further suggested that Hp infection and age may be one of the causes of atrophic gastritis. Meta-analysis studies showed that the risk of gastric cancer is reduced after Hp eradication, and the benefit varied with or without precancerous lesion [26, 27]. Extensive testing and treatment of Hp in general population is effective and necessary.

Serum PG can reflect the morphological and functional status of gastric mucosa. PGI is produced by gastric fundus gland cells, and its decrease rate is related to the increase of gastric atrophy, while PGII has a greater correlation with gastric fundus mucosa lesions (relative to gastric antrum mucosa), and its increase is related to gastric fundus duct atrophy, intestinal metaplasia or pseudopylori metaplasia and dysplasia. Progressive reduction of PGR is associated with progressive gastric mucosal atrophy and gastric cancer [1]. A meta-analysis of 31 studies including 1520 patients with gastric cancer and 2265 patients with atrophic gastritis found that serum PG has great potential as a non-invasive, population-based screening tool for gastric cancer and atrophic gastritis [2]. Zoalfaghari [13] confirmed that serum PGI and PGR are potential serological markers for the screening of atrophic gastritis with high sensitivity and specificity. However, PG cutoff values varied in different studies, and the cut-off values of domestic studies were also inconsistent [5,6,7,8, 11, 12]. Our previous study found that the cutoff value for the diagnosis of atrophic gastritis was PGI ≤ 50.3 ng/ml, and there were differences between the Hp infected group and the non Hp-infected group [10]. Therefore, we conducted this study to explore whether the differences of the above cut-off values were due to the different baseline PG levels.

In this study, there were significant differences in baseline PG levels among the different regions in China. In terms of PGR, we found significant differences between Northeast and Southwest China. As shown in Tables 3 and 4, there were differences in the baseline data from different regions, especially in the Hp infection rate. Therefore, those differences of baseline PG levels may be related to these baseline data. Interestingly, there were significant differences in nationality, age, dietary habits, smoking, and Hp infection rates between Eastern China and Central/Northern China, but we found no difference in PGR levels. However, there were significant differences in PGR levels between Eastern China and Southwest China, and we found no differences in gender, smoking, age and Hp infection rate except for dietary habits and national differences. Above results suggests that in the follow-up studies of evaluating the PG cutoff values in China, it may be necessary to further consider the influence of ethnic groups (Southern, Northeast and Southwest China are the areas where ethnic minorities gather), dietary habits, Hp infection and other factors, and a larger sample and multi-center study is needed to explore the diagnostic criteria in China.


In conclusion, the baseline PG levels varied in different regions of China. The influencing factors include age, nationality, dietary habits, smoking and Hp infection rate, and so on. In the follow-up studies of PG cut-off value, different PG cut-off values based on regions may be more effective in the screening of gastric cancer and precancerous lesions.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.



Atrophic gastritis


Gastric cancer

Hp :

Helicobacter pylori


Intestinal metaplasia


Operative Link on Gastritis Assessment




Pepsinogen I


Pepsinogen II


PGI/PGII ratio


  1. 1.

    Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels —“ABC method.” Proc Jpn Acad. 2011;87(7):405–14.

    Article  Google Scholar 

  2. 2.

    Huang YK, Yu JC, Kang WM, et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLoS ONE. 2015;10(11):e0142080.

    Article  Google Scholar 

  3. 3.

    Zoalfaghari A, Aletaha N, Roushan N, Taslimi R, Foroutan H, Faridnia B. Accuracy of pepsinogens for early diagnosis of atrophic gastritis and gastric cancer in Iranian population. Med J Islam Repub Iran. 2014;28(1):150–150.

    PubMed  PubMed Central  Google Scholar 

  4. 4.

    Ikeda F, Shikata K, Hata J, et al. Combination of Helicobacter pylori antibody and serum pepsinogen as a good predictive tool of gastric cancer incidence: 20-year prospective data from the Hisayama Study. J Epidemiol. 2016;26(12):629–36.

    Article  Google Scholar 

  5. 5.

    Jan B, Michael S, Thomas W, Doerthe K, Peter M. Serological assessment of gastric mucosal atrophy in gastric cancer. BMC Gastroenterol. 2012;12(1):10.

    Article  Google Scholar 

  6. 6.

    Leja M, Kupcinskas L, Funka K, et al. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci. 2009;134(4):A-478.

    Google Scholar 

  7. 7.

    Kikuchi S, Kato M, Katsuyama T, Tominaga S, Asaka M. Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection. Helicobacter. 2010;11(3):147–51.

    Article  Google Scholar 

  8. 8.

    Nasrollahzadeh D, Aghcheli K, Sotoudeh M, et al. Accuracy and cut-off values of pepsinogens I, II and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis. PLoS ONE. 2011;6(10):e26957.

    CAS  Article  Google Scholar 

  9. 9.

    Kang JM, Kim N, Yoo JY, et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter. 2010;13(2):146–56.

    Article  Google Scholar 

  10. 10.

    Tong YL, Wu YL, Song ZY, et al. The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China: a diagnostic clinical research. BMC Gastroenterol. 2017;17:88.

    Article  Google Scholar 

  11. 11.

    He CY, Sun LP, Gong YH, Xu Q, Dong NN, Yuan Y. Serum pepsinogen II: a neglected but useful biomarker to differentiate between diseased and normal stomachs. J Gastroenterol Hepatol. 2011;26(6):1039–46.

    CAS  Article  Google Scholar 

  12. 12.

    Wu KC, Li HT, Qiao TD, Li CN, Ji WS, Tian FQ, et al. Diagnosis of atrophic body gastritis in Chinese patients by measuring serum pepsinogen. Chin J Dig Dis. 2004;5(1):22–7.

    CAS  Article  Google Scholar 

  13. 13.

    Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161–81.

    CAS  Article  Google Scholar 

  14. 14.

    Zhou Y, Li HY, Zhang JJ, et al. Operative link on gastritis assessment stage is an appropriate predictor of early gastric cancer. World J Gastroenterol. 2016;22:3670–8.

    Article  Google Scholar 

  15. 15.

    Namekata T, Miki K, Kimmey M, et al. Chronic atrophic gastritis and Helicobacter pylori infection among Japanese Americans in Seattle. Am J Epidemiol. 2000;151:820–30.

    CAS  Article  Google Scholar 

  16. 16.

    Cheli R, Simon L, Aste H, Figus IA, Nicolo G, Bajtai A, et al. Atrophic gastritis and intestinal metaplasia in asymptomatic Hungarian and Italian populations. Endoscopy. 1980;12:105–8.

    CAS  Article  Google Scholar 

  17. 17.

    Kato I, Tominaga S, Ito Y, Kobayashi S, Yoshii Y, Matsuura A, et al. Atrophic gastritis and stomach cancer risk: cross-sectional analyses. Jpn J Cancer Res. 1992;83:1041–6.

    CAS  Article  Google Scholar 

  18. 18.

    Kato I, Tominaga S, Ito Y, Kobayashi S, Yoshii Y, Matsuura A, et al. A prospective study of atrophic gastritis and stomach cancer risk. Jpn J Cancer Res. 1992;83:1137–42.

    CAS  Article  Google Scholar 

  19. 19.

    de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134:945–52.

    Article  Google Scholar 

  20. 20.

    Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol. 2005;36:228–33.

    Article  Google Scholar 

  21. 21.

    Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008;40:650–8.

    CAS  Article  Google Scholar 

  22. 22.

    Rugge M, Megggio A, Pravadelli C, Barbareschi M, Fassan M, Gentilini M, et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut. 2019;68(1):11–7.

    Article  Google Scholar 

  23. 23.

    Rugge M, Genta RM, Fassan M, Valentini E, Coati I, Guzzinati S, Savarino E, Zorzi M, Farinati F, Malfertheiner P. OLGA gastritis staging for the prediction of gastric cancer risk: a long-term follow-up study of 7436 patients. Am J Gastroenterol. 2018;113(11):1621–8.

    Article  Google Scholar 

  24. 24.

    Rugge M, de Boni M, Pennelli G, de Bona M, Giacomelli L, Fassan M, et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinicopathological follow-up study. Aliment Pharmacol Ther. 2010;31:1104.

    CAS  PubMed  Google Scholar 

  25. 25.

    Quach DT, Le HM, Nguyen OT, Nguyen TS, Uemura N. The severity of endoscopic gastric atrophy could help to predict Operative Link on gastritis assessment gastritis stage. J Gastroenterol Hepatol. 2011;26:281–5.

    Article  Google Scholar 

  26. 26.

    Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.

    Article  Google Scholar 

  27. 27.

    Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2020;7(7):CD005583.

    PubMed  Google Scholar 

Download references


This research was supported by the Health Management Center, the Endoscopy Center, the Digestive Department and the Institute for Cancer Research at the Second Affiliated Hospital of Zhejiang University, Jilin City People’s Hospital, No. 924 Hospital of the People’s Liberation Army of China, Kunshan Hospital of Traditional Chinese Medicine, Chinese PLA General Hospital, Sichuan Provincial People's Hospital, The First Hospital Affiliated to AMU (Southwest Hospital), Zhongshan Hospital Affiliated to Xiamen University, Jingzhou Hospital of Traditional Chinese Medicine and Shanghai Changhai Hospital. We express our gratitude to all study participants for their support.


The work of Tong YL was supported by the National Natural Science Foundation of China (#71804161) and the Zhejiang Province Major Disease Diagnosis and Treatment Technology Research Center (#17-2018-%s-0077). The work of Song ZY was supported by the China Foundation for Health Promotion (#CHPF-2015-WASC-001).

Author information




TYL analyzed and interpreted the data, and was a major contributor in writing the manuscript. SZY made substantial contributions to conception and design; ZY, WHG, HXJ, XHW, LH, SP, GLR, WHB, XHZ, LYH, LSZ contributions to acquisition of data. WD was involved in revising it critically for important intellectual content. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Zhenya Song.

Ethics declarations

Ethics approval and consent to participate

The study was approved and authorized by the ethics committees of various participating hospitals (approval #2015-079 at the Second Affiliated Hospital of Zhejiang University College of Medicine, the leading site). Informed consent was obtained from all individuals included in this study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tong, Y., Wang, H., Zhao, Y. et al. Serum pepsinogen levels in different regions of China and its influencing factors: a multicenter cross-sectional study. BMC Gastroenterol 21, 264 (2021).

Download citation


  • Serum pepsinogen
  • Different regions of China
  • Influencing factors
  • Baseline survey